勃林格殷格翰和Zealand Pharma(纳斯达克股票代码:ZEAL)6月24日公布试验数据表明,在接受46周治疗、不伴有2型糖尿病的超重或肥胖受试者中,Survodutide(又称为BI 456906)的疗效优于安慰剂。1上述发现已在美国加利福尼亚州圣地亚哥举行...
· 在接受Survodutide(BI 456906)治疗的两个最高剂量组中,高达40%的受试者体重下降至少20%1 · Survodutide具有新的作用机制(GCG/GLP-1双受体激动剂),在降低食欲的同时,还能直接影响肝脏的能量消耗2 ·详…
1. le Roux CW et al. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity. Presented at the American Diabetes Association’s 83rd Scientific Sess...
1. le Roux CW et al. A Phase 2, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of BI 456906 in People with Overweight/Obesity. Presented at the American Diabetes Association’s 83rd Scientific Sessions 2023; 23 June 2023. 51-OR. 2. T. Zimmerman et al. BI 456906: Dis...
药融圈获悉:德国殷格翰和丹麦哥本哈根,2023年6月23日-勃林格殷格翰和Zealand Pharma(纳斯达克股票代码:ZEAL)今天公布试验数据表明,在接受46周治疗、不伴有2型糖尿病的超重或肥胖受试者中,Survodutide(又称为BI 456906)的疗效优于安慰剂。1 上述发现已在美国加利福尼亚州圣地亚哥举行的2023年美国糖尿病协会第83届...
2023年6月24日，勃林格殷格翰和Zealand Pharma公布试验数据表明，在接受46周治疗、不伴有2型糖尿病的超重或肥胖受试者中，Survodutide（又称为BI 456906）的疗效优于安慰剂[1]。上述发现已在美国加利福尼亚州圣地亚哥举行的2023年美国糖尿病协会第83届大会上公布。II期研究包括两项分析：计划治疗分析（随机分组时...
A Phase II, randomized, double-blind, placebo-controlled, dose-finding study of survodutide (BI 456906) in people living with overweight/obesitydoi:10.1016/j.metabol.2024.155848M. Carel W. Le RouxSchool of Medicine, St. Vincent's University Hospital and University College Dublin, Dublin, ...
“We believe that BI 456906 has great therapeutic potential, and we are thrilled to see it advance into Phase 2 development,” said Emmanuel Dulac, President and Chief Executive Officer at Zealand Pharma. “Our strong partnership with Boehringer Ingelheim unites expertise and capabilities to achieve...
Here, we describe the discovery and characterization of BI 456906, a once-weekly, injectable GCGR/GLP-1R dual agonist currently in Phase II clinical development for obesity, type 2 diabetes, and NASH. We describe biomarkers that were applied in the discovery of BI 456906 as a balanced dual ag...
OS-119 Survodutide (BI 456906), a glucagon receptor/glucagon-like peptide-1 receptor (GCGR/GLP-1R) dual agonist, in people with compensated and decompensated cirrhosis: a multinational, open-label, phase 1 trial 来自 dx.doi.org 喜欢 0 阅读量: 10 ...